+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

All Ages
All Genders
ID06355934

Observational Multi-Country Study of Real-World Characteristics, Treatments, and Outcomes in Patients with ATTR Amyloidosis

Led by AstraZeneca · Updated on 2026-09-09

52121

Participants Needed

29

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This observational study focuses on patients with ATTR amyloidosis, aiming to gather real-world data on their disease journeys before and after diagnosis. It seeks to describe patient characteristics, treatment patterns, and outcomes, including clinical, economic, and quality of life measures. The study also aims to better understand how ATTR amyloidosis presents and affects daily living. The study does not involve any interventions, as it is a retrospective analysis of existing data from multiple countries. It includes patients with various types of ATTR amyloidosis, such as cardiomyopathy, neuropathy, wild type, hereditary, and mixed phenotypes. Data collected cover the period from before diagnosis up to the end of follow-up, which can last up to 12 years. Participants medical records will be reviewed to assess healthcare resource use, clinical measurements like neuropathy impairment scores, and humanistic outcomes such as quality of life and activities of daily living. The study will evaluate hospitalizations, outpatient visits, emergency visits, transplant events, and mortality over time. This long-term data collection helps characterize disease impact and resource use for patients with ATTR amyloidosis.

CONDITIONS

Brief Title

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

Research Team

A

AstraZeneca Clinical Study Information Center

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here